ArticleJournal for immunotherapy of cancer2017

Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.

Rocio Garcia-Carbonero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.